Please use this identifier to cite or link to this item: https://dspace.uzhnu.edu.ua/jspui/handle/lib/32549
Full metadata record
DC FieldValueLanguage
dc.contributor.authorГряділь, Тарас Іванович-
dc.contributor.authorGriadil, Taras Ivanovych-
dc.contributor.authorChopey, Ivan Vasylovych-
dc.contributor.authorЧопей, Іван Васильович-
dc.contributor.authorDebreceni, Kristian Oleksandovich-
dc.contributor.authorHechko, Mykhaylo Mykhailovych-
dc.contributor.authorГечко, Михайло Михайлович-
dc.contributor.authorMykhalko, Yaroslav Omelianovych-
dc.contributor.authorМихалко, Ярослав Омелянович-
dc.contributor.authorChubirko, Ksenia Ivanivna-
dc.contributor.authorЧубірко, Ксенія Іванівна-
dc.contributor.authorFeysa, Snizhana Vasylovna-
dc.contributor.authorФейса, Сніжана Василівна-
dc.date.accessioned2021-01-19T15:54:06Z-
dc.date.available2021-01-19T15:54:06Z-
dc.date.issued2020-03-
dc.identifier.citationGriadil T.I. Comparison of the effect of dapagliflozin on contrast to standard therapy of the patients with type 2 diabetes mellitus and concomitant obesity, their effect on laboratory and anthropometric parameters / T.I. Griadil, I.V.Chopey, K.I. Chubirko // Wiadomości Lekarskie. — 2020. — tom LXXIII. — Nr 3. — Marzec /March — PP. 457-461.uk
dc.identifier.urihttps://dspace.uzhnu.edu.ua/jspui/handle/lib/32549-
dc.description.abstractABSTRACT The aim: Evaluate clinical and laboratory parameters of the patients with type 2 diabetes mellitus and concomitant obesity after a course of dapagliflozin treatment and compare with a standard treatment regimen. Materials and methods: Conducted a comprehensive clinical laboratory examination and measurement of the anthropometric parameters of the patients with type 2 diabetes mellitus and concomitant obesity, with subsequent statistical calculations. Results: The data obtained at different stages of the study revealed a statistically significant effect of glucose treatment and glycosylated hemoglobin (HbA1c). Since the 6th month of dapagliflozin treatment, we have shown a tendency to lose weight compared to baseline in this group of patients and controls. Conclusions: Type 2 diabetes mellitus and obesity significantly increase the risk of developing a number of complications. Complex control and effects on clinical laboratory and anthropometric parameters can statistically significantly influence the development of the complications, and in this context, dapaglifloflozin showed statistically better results than standard metformin monotherapy. KEY WORDS: type 2 diabetes mellitus, obesity, treatment, diagnosticsuk
dc.language.isoukuk
dc.publisherWydawnictwo Aluna ul. Z.M. Przesmyckiego 29, 05-510 Konstancin-Jeziorna Prosimy o dokonywanie wpłat na numer rachunku Wydawnictwa: Credit Agricole Bank Polska S. A.: 82 1940 1076 3010 7407 0000 0000uk
dc.relation.ispartofseriesTOM LXXIII;-
dc.relation.ispartofseries2020;-
dc.relation.ispartofseriesNr 3;-
dc.relation.ispartofseriesmarzec;-
dc.subjecttype 2 diabetes mellitusuk
dc.subjectobesityuk
dc.subjecttreatmentuk
dc.subjectdiagnosticsuk
dc.titleComparison of the effect of dapagliflozin on contrast to standard therapy of the patients with type 2 diabetes mellitus and concomitant obesity, their effect on laboratory and anthropometric parametersuk
dc.typeTextuk
dc.pubTypeСтаттяuk
Appears in Collections:Наукові публікації кафедри терапії та сімейної медицини



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.